Merck's Keytruda boosts response in hard-to-treat lung cancer

(Reuters) – The combination of Merck & Co’s immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *